We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ID Biomedical has completed analysis of the vaccine immunogenicity and safety
data from its 2003-2004 field efficacy trial of FluINsure, a nonliving intranasally
delivered influenza vaccine.
Palatin Technologies has completed enrollment in separate Phase IIa clinical
trials evaluating PT-141 in patients experiencing female sexual dysfunction
(FSD) and male erectile dysfunction (ED).
Myriad Genetics has initiated enrollment in a Phase III human clinical trial
of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's
disease.
Sepracor has announced the preliminary results of a Phase IIIb/IV, 545-patient,
double-blind, placebo-controlled, 10-week study evaluating the efficacy and
safety of Lunesta brand eszopiclone in patients with insomnia and co-existing
major depressive disorder (MDD).
Advanced Magnetics has initiated a large-scale, multicenter Phase III safety
study for ferumoxytol, the company's next-generation product in its development
pipeline, for use as an intravenous iron replacement therapeutic in anemic chronic
kidney disease patients, regardless of whether they are on dialysis.
Neurocrine Biosciences plans to resubmit its new drug application (NDA) for
indiplon modified release (MR) tablets to update its electronic formatting.
Corgentech has filed an investigational new drug application with the FDA to
begin a Phase I/II clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug
candidate for the treatment of atopic dermatitis, a chronic skin disease also
known as eczema.
Product liability law firm Hersh & Hersh has filed a lawsuit in San Francisco
Superior Court on behalf of plaintiff Linda Iacovetta against Valeant, a Southern
California drug company, and California Pacific Medical Center (CPMC) in San
Francisco.